Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience

被引：0
|
作者：
Okunaka, Mashiro
Kotani, Daisuke
Demachi, Ken
Kawazoe, Akihito
Yoshino, Takayuki
Shitara, Kohei
机构：
[1] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[4] Natl Canc Ctr Hosp East, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
322
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer
    Nakajima, Takako Eguchi
    Kadowaki, Shigenori
    Minashi, Keiko
    Nishina, Tomohiro
    Yamanaka, Takeharu
    Hayashi, Yuichiro
    Izawa, Naoki
    Muro, Kei
    Hironaka, Shuichi
    Kajiwara, Takeshi
    Kawakami, Yutaka
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1029 - 1036
  • [22] Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer
    Li, Xiaofen
    Zhou, Nan
    Yang, Yu
    Lu, Zijian
    Gou, Hongfeng
    CANCER SCIENCE, 2024, 115 (07) : 2371 - 2383
  • [23] Ramucirumab plus paclitaxel for gastric cancer in China
    Yoon, Harry H.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (12): : 975 - 976
  • [24] Nab-paclitaxel as second-line treatment in advanced biliary cancer
    Unseld, M.
    Kornek, G.
    Werner, S.
    Guenther, S.
    Christoph, Z.
    Gerald, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S431 - S432
  • [25] Paclitaxel combined with ramucirumab as the second-line chemotherapy for elderly patients with advanced gastric cancer.
    Kusumoto, Tetsuya
    Uehara, Hideo
    Hashimoto, Kenkichi
    Fujinaka, Yoshihiko
    Yoshinaga, Keiji
    Kusumoto, Eiji
    Shinzato, Chiaki
    Sakaguchi, Yoshihisa
    Ikejiri, Koji
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A randomized phase II trial of paclitaxel plus ramucirumab versus nab-paclitaxel plus ramucirumab for gastric cancer with peritoneal dissemination refractory to first-line therapy (WJOG10617G/P-SELECT)
    Hirata, Kenro
    Hamamoto, Yasuo
    Shoji, Hirokazu
    Hara, Hiroki
    Kondoh, Chihiro
    Yasui, Hisateru
    Kajiwara, Takeshi
    Baba, Eishi
    Ando, Takayuki
    Sugimoto, Naotoshi
    Okano, Naohiro
    Kawakami, Hisato
    Katsuya, Hiroo
    Nagase, Michitaka
    Moriwaki, Toshikazu
    Yoshimura, Kenichi
    Ando, Masahiko
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] Initial Experience with Nab-Paclitaxel for Patients with Advanced Gastric Cancer: Safety and Efficacy
    Kanazawa, Yoshikazu
    Fujita, Itsuo
    Kakinuma, Diasuke
    Arai, Hiroki
    Matsuno, Kunihiko
    Shimoda, Tomohiro
    Ko, Kazuhide
    Kato, Shunji
    Uchida, Eiji
    ANTICANCER RESEARCH, 2017, 37 (05) : 2715 - 2720
  • [28] Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study
    Kashiwada, A.
    Nishioka, A.
    Aragane, N.
    Kimura, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
    Li, Sini
    Peng, Liubao
    Tan, Chongqing
    Zeng, Xiaohui
    Wan, Xiaomin
    Luo, Xia
    Yi, Lidan
    Li, Jianhe
    PLOS ONE, 2020, 15 (05):
  • [30] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
12345